MXPA04004903A - Derivados de aminoacido utiles para el tratamiento de la enfermedad de alzheimer. - Google Patents

Derivados de aminoacido utiles para el tratamiento de la enfermedad de alzheimer.

Info

Publication number
MXPA04004903A
MXPA04004903A MXPA04004903A MXPA04004903A MXPA04004903A MX PA04004903 A MXPA04004903 A MX PA04004903A MX PA04004903 A MXPA04004903 A MX PA04004903A MX PA04004903 A MXPA04004903 A MX PA04004903A MX PA04004903 A MXPA04004903 A MX PA04004903A
Authority
MX
Mexico
Prior art keywords
group
compound
lysine
beta
preparation
Prior art date
Application number
MXPA04004903A
Other languages
English (en)
Spanish (es)
Inventor
John Varghese
Original Assignee
Elan Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elan Pharm Inc filed Critical Elan Pharm Inc
Publication of MXPA04004903A publication Critical patent/MXPA04004903A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/325Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/18Sulfonamides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • A61K31/405Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Indole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
MXPA04004903A 2001-11-21 2002-11-21 Derivados de aminoacido utiles para el tratamiento de la enfermedad de alzheimer. MXPA04004903A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33469201P 2001-11-21 2001-11-21
PCT/US2002/037360 WO2003045378A1 (en) 2001-11-21 2002-11-21 Amino acid derivatives useful for the treatment of alzheimer's disease

Publications (1)

Publication Number Publication Date
MXPA04004903A true MXPA04004903A (es) 2005-06-06

Family

ID=23308367

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA04004903A MXPA04004903A (es) 2001-11-21 2002-11-21 Derivados de aminoacido utiles para el tratamiento de la enfermedad de alzheimer.

Country Status (10)

Country Link
US (1) US20060079550A1 (https=)
EP (1) EP1458378B1 (https=)
JP (1) JP2005514370A (https=)
AT (1) ATE326964T1 (https=)
AU (1) AU2002356991A1 (https=)
BR (1) BR0214359A (https=)
CA (1) CA2477585A1 (https=)
DE (1) DE60211746D1 (https=)
MX (1) MXPA04004903A (https=)
WO (1) WO2003045378A1 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2471099C (en) * 2001-12-20 2011-04-12 Bristol-Myers Squibb Company .alpha.-(n-sulphonamido)acetamide derivatives as .beta.-amyloid inhibitors
US7521481B2 (en) 2003-02-27 2009-04-21 Mclaurin Joanne Methods of preventing, treating and diagnosing disorders of protein aggregation
US7230133B2 (en) 2003-05-01 2007-06-12 Bristol-Myers Squibb Company Malonamides and malonamide derivatives as modulators of chemokine receptor activity
CA2535337A1 (en) * 2003-08-14 2005-03-03 Merck & Co., Inc. Macrocyclic beta-secretase inhibitors for the treatment of alzheimer's disease
EP1673078B1 (en) * 2003-10-03 2008-05-28 Merck & Co., Inc. Benzylether and benzylamino beta-secretase inhibitors for the treatment of alzheimer's disease
CA2544350A1 (en) * 2003-10-29 2005-05-12 Elan Pharmaceuticals, Inc. N-substituted benzene sulfonamides
ATE517861T1 (de) * 2003-11-24 2011-08-15 Merck Sharp & Dohme Benzylether und benzylaminoverbindungen als inhibitoren von beta-secretase zur behandlung von alzheimer-krankheit
NZ562314A (en) 2005-04-08 2010-02-26 Comentis Inc Compounds which inhibit beta-secretase activity and methods of use thereof
GB0621973D0 (en) * 2006-11-03 2006-12-13 Philogen Spa Binding molecules and uses thereof
CA2758016A1 (en) 2008-06-05 2009-12-10 Novotyr Therapeutics Ltd. Novel modulators of protein kinase signaling
CN103242200A (zh) * 2013-04-10 2013-08-14 吉尔生化(上海)有限公司 一种Nα-芴甲氧羰基-Nε-乙酰基-赖氨酸的制备方法
EP3021944B1 (en) 2013-07-14 2018-12-19 Yissum Research Development Company of the Hebrew University of Jerusalem, Ltd. Igf-1r signaling pathway inhibitors useful in the treatment of neurodegenerative diseases
CN107250108B (zh) 2015-02-05 2020-11-27 特尔诺沃有限公司 用于治疗癌症的irs/stat3双重调节剂与抗癌剂的组合
CN109265371A (zh) * 2018-10-12 2019-01-25 吉尔生化(上海)有限公司 一种Nα-[(9H-芴-9-基甲氧基)羰基]-Nε-乙酰基-L-赖氨酸的制备方法
CN109824547A (zh) * 2019-03-20 2019-05-31 康化(上海)新药研发有限公司 一种双不同保护氨基酸的合成方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6251928B1 (en) * 1994-03-16 2001-06-26 Eli Lilly And Company Treatment of alzheimer's disease employing inhibitors of cathepsin D
US5986102A (en) * 1998-04-29 1999-11-16 Pharmacopeia, Inc. Hydroxypropylamide peptidomimetics as inhibitors of aspartyl proteases
PL205294B1 (pl) * 1998-09-24 2010-03-31 Upjohn Co Izolowany lub oczyszczony polipeptyd, oczyszczony lub izolowany polinukleotyd, wektor, wektor ekspresyjny, komórka gospodarza, sposób wytwarzania polipeptydu, sposoby identyfikowania czynnika obniżającego, modulującego lub hamującego aktywność, zastosowanie takiego czynnika, izolowany kwas nukleinowy, obejmujący go wektor i ich zastosowanie, sposoby zmniejszania komórkowego wytwarzania beta amyloidu i zastosowanie antysensownego reagenta
US6455587B1 (en) * 2000-03-15 2002-09-24 Pharmacor Inc. Amino acid derivatives as HIV aspartyl protease inhibitors

Also Published As

Publication number Publication date
DE60211746D1 (de) 2006-06-29
BR0214359A (pt) 2004-10-13
JP2005514370A (ja) 2005-05-19
WO2003045378A1 (en) 2003-06-05
CA2477585A1 (en) 2003-06-05
US20060079550A1 (en) 2006-04-13
ATE326964T1 (de) 2006-06-15
AU2002356991A1 (en) 2003-06-10
EP1458378B1 (en) 2006-05-24
EP1458378A1 (en) 2004-09-22

Similar Documents

Publication Publication Date Title
EP1458378B1 (en) Amino acid derivatives useful for the treatment of alzheimer's disease
US20050038019A1 (en) Hydroxy substituted amides for the treatment of alzheimer's disease
CA2462875A1 (en) Allylamides useful in the treatment of alzheimer's disease
WO2005087714A2 (en) Methods of treatment of amyloidosis using bi-cyclic aspartyl protease inhibitors
EP1729755A1 (en) Methods of treatment of amyloidosis using aspartyl-protease inihibitors
JP2007528404A (ja) 置換された尿素およびカルバメート、フェナシル−2−ヒドロキシ−3−ジアミノアルカン、ならびにベンズアミド−2−ヒドロキシ−3−ジアミノアルカン系のアスパラギン酸プロテアーゼ阻害薬
US7459476B2 (en) Methods for treating Alzheimer's disease using hydroxyethylene compounds containing a heterocyclic amide bond isostere
MXPA04001980A (es) Metodos de tratamiento de la enfermedad de alzheimer usando derivados de quinaldoil.amina de hidrocarburos substituidos con oxo e hidroxi.
JP2005505517A (ja) アルツハイマー病を治療するためのアミンジオール
US20050159460A1 (en) Peptide isosteres containing a heterocycle useful in the treatment of alzheimer's disease
MXPA05003220A (es) Compuestos para tratamiento de enfermedad de alzheimer.
EP1401439B1 (en) Use of bicyclo compounds for treating alzheimer's disease
WO2004037179A2 (en) Substituted peptides useful in the treatment of alzheimer’s disease
US20080103176A1 (en) Substituted Hydroxyethylamines
US20050080141A1 (en) Amino diols useful in the treatment of alzheimer's disease
EP1712227A1 (en) Amino diols useful in the treatment of Alzheimer's disease
WO2007110727A2 (en) Amide stabilized hydroxyethylamines
CA2590222A1 (en) Heterocycloalkyl-benzyl substituted hydroxyethlamines

Legal Events

Date Code Title Description
FA Abandonment or withdrawal